Diagnostics and research stocks with the highest free cash flow yield

Ranked

28

of 74 diagnostics and research stocks we cover

Median

2.7%

Highest

8.7%

FTRE

Range

0.1% to 8.7%

#	Company	FCF yield	PE	Revenue growth (TTM)	Market cap
1	FTREFortrea	8.7%	n/m	−2.1%	$2.2B
2	LNTHLantheus	6.0%	24.2×	+2.3%	$6.5B
3	DGXQuest Diagnostics	5.1%	25.7×	+9.1%	$26.7B
4	IQVIQVIA	4.7%	34.7×	+8.2%	$46B
5	ICCCImmucell	4.5%	128×	+8.5%	$93.1M
6	NRCNRC Health	4.5%	87.7×	−0.2%	$485.1M
7	LHLabcorp	4.3%	27.2×	+6.4%	$26.7B
8	VCYTVeracyte	4.3%	34.2×	+17.3%	$3.9B
9	AVTRAvantor	3.9%	n/m	−1.6%	$11.7B
10	MEDPMedpace	3.8%	39.2×	+24.7%	$18.7B
11	BIOBio-Rad Laboratories	3.6%	44.8×	+1.4%	$9.9B
12	DHRDanaher	3.4%	40.9×	+4.6%	$162B
13	RVTYRevvity	3.2%	75.6×	+4.1%	$17.7B
14	IDXXIDEXX Laboratories	2.8%	39.4×	+12.8%	$44.1B
15	AAgilent Technologies	2.6%	34.0×	+8.6%	$48.8B
16	MTDMettler-Toledo International	2.6%	37.6×	+6.9%	$33.5B
17	ILMNIllumina	2.3%	50.1×	+4.9%	$40.7B
18	CRLCharles River Laboratories International	2.2%	n/m	−0.7%	$16.5B
19	PRPOPrecipio	2.2%	n/m	+28.0%	$35.8M
20	NEOGNeogen	1.9%	n/m	−0.3%	$2.7B
21	CAICaris Life Sciences	1.4%	86.5×	+85.4%	$9B
22	RDNTRadNet	1.3%	n/m	+18.9%	$5.5B
23	TXG10x Genomics	1.3%	n/m	−4.3%	$9.3B
24	BRKRBruker	1.1%	n/m	+1.6%	$8.8B
25	WATWaters	0.9%	113×	+52.5%	$44.6B
26	BLLNBillionToOne	0.7%	166×	+90.1%	$5.1B
27	NTRANatera	0.1%	n/m	+37.8%	$58.2B
28	MASS908 Devices	0.1%	n/m	+13.4%	$474.9M

Not ranked: 31 with no positive free cash flow, 7 with not a meaningful number, 1 with a yield above 40% (usually a one-off). 7 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.